Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VSF1.01 for Reduction of Cochlear Implant Surgery Related Trauma (ESCRT)
2024-512498-29-00Phase 2Authorised
- Sponsor
- Medizinische Hochschule Hannover
- Start
- Oct 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of VSF1.01 in Hypoacusis, sensorineural hearing loss (SNHL), Profound Deafness and 1 more, sponsored by Medizinische Hochschule Hannover. Primary endpoint: Safety profile via adverse events. Planned start Oct 2024; status: authorised.
02
Drugs
VSF1.01
03
Conditions
Hypoacusissensorineural hearing loss (SNHL)Profound DeafnessFunctional deafness (FD)
Beyond the preview
Go deeper on 2024-512498-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512498-29-00.